SGHT · Sight Sciences, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on SGHT. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About SGHT · Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Live Quote
HOLD (score +4) · 12-1 mom 20.7% · RSI 63.8 · above_both · -40.2% from high
Targets blend Wall Street consensus (4 analysts: low $5.15 / mean $8.54 / high $12.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Triggered anti-signal gates for going concern, dilution, and accounting flags. The dossier lacks smart-money accumulation, sustained options flow, or quantifiable mispricing to offset the high appellate risk and ongoing cash burn.
Triggered anti-signal gates for going concern, dilution, and accounting flags. The dossier lacks smart-money accumulation, sustained options flow, or quantifiable mispricing to offset the high appellate risk and ongoing cash burn.
Sight Sciences makes ophthalmic surgical devices for glaucoma (OMNI Surgical System) and dry eye disease (TearCare). The investigation trigger — 3 Form 4 filings in 14 days — was met (June 4-5, 2026), but all three were director RSU grants under the Non-Employee Director Compensation Program at $0.00 price, NOT open-market purchases. This is a critical distinction: the smart-money signal is noise. However, two genuinely material catalysts exist: (1) A March 27, 2026 Delaware federal court ruling preserving a jury verdict of willful patent infringement against Alcon's Hydrus Microstent and awarding $34M in damages plus an ongoing 10% royalty through November 2028 — potentially worth hundreds of millions if collected. (2) Q1 FY26 earnings beat on May 6, 2026 with revenue guidance raised for full-year 2026. The company is deeply unprofitable (forward P/E N/M), burning $7-13M cash per quarter, and the stock trades ~52% below its 52-week high of $9.05. Valuation at current prices reflects substantial skepticism about execution; if the Alcon damages are ultimately collected without reversal on appeal, SGHT's financial trajectory transforms materially.